Abstracts Archive - Page 460 of 2607 - ACR Meeting Abstracts

Abstract Number: 2222 • ACR Convergence 2023
Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides
Juliane Michel¹, Clément Prati², Lucine Vuitton³, Eric Toussirot⁴, Charline Vauchy⁵, Daniel Wendling⁶ and frank Verhoeven², ¹Rheumatology, CHU Besancon, Besançon, France, ²Service de rhumatologie, CHU de Besançon, Besançon, France, ³Gastroenterology, CHU Besancon, Besançon, France, ⁴University Hospital of Besancon, Besançon, France, ⁵INSERM CIC-1431, Besançon, France, ⁶Besançon University Hospital, Besançon, France
Background/Purpose: There is a pathophysiological link between spondyloarthritis (SpA) and Inflammatory Bowel Disease (IBD), so that 10% of IBD is estimated to have SpA and…
Abstract Number: 2228 • ACR Convergence 2023
Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment
William R Tillett¹, Laura Coates², marijn vis³, Enrique Soriano⁴, Joseph F. Merola⁵, Miriam Zimmermann⁶, May Shawi⁷, Mohamed Sharaf⁸, Peter Nash⁹ and Philip Helliwell¹⁰, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁷Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹School of Medicine, Griffith University, Brisbane, Australia, ¹⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19 subunit inhibitor, was shown to reduce mean changes in radiographic progression vs placebo (PBO) by week (W)24 and…
Abstract Number: 2213 • ACR Convergence 2023
Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach
Imke Redeker¹, Styliani Tsiami², Jan Eicker³, Uta Kiltz⁴, David Kiefer², Ioana Andreica⁵, Philipp Sewerin² and Xenofon Baraliakos⁶, ¹Ruhr Universität Bochum, Bochum, Germany, ²Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne and Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: In axial spondyloarthritis (axSpA), early diagnosis plays a key role in preventing disease progression. However, a validated diagnostic algorithm does not exist, while classification…
Abstract Number: 2204 • ACR Convergence 2023
Residual Disease Activity in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA)
Denis Choquette¹, Walter P. Maksymowych², Proton Rahman³, Robert Inman⁴, Marie-Claude Laliberté⁵, Pierre-Andre Fournier⁶, Tanya Girard⁵ and Dafna Gladman⁷, ¹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵AbbVie, Inc., Saint-Laurent, QC, Canada, ⁶AbbVie, Inc., Montréal, QC, Canada, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: In patients with axial spondyloarthritis (axSpA), treatment goals consist of achieving remission or low disease activity (LDA) to alleviate symptoms, improve function, decrease disease…
Abstract Number: 2235 • ACR Convergence 2023
Identifying Differentially Expressed Genes to Predict TNF-Alpha and IL-17A Inhibitor Response in Psoriatic Arthritis
Quan Li¹, Darren O'Rielly¹, Kari Jenkins¹, Dianne Codner¹, Dafna Gladman², Amanda Dohey¹, Igor Jurisica³, Vinod Chandran⁴ and Proton Rahman⁵, ¹Memorial University, St. John's, NL, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁵Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada
Background/Purpose: Approximately 30 to 40% of patients are primary non-responders, and the response rate declines after each successive biological therapy. The primary aim is to…
Abstract Number: 2221 • ACR Convergence 2023
Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers
Lourdes Ladehesa Pineda¹, Ivan Arias de la Rosa², Laura Cuesta-López³, Clementina López Medina⁴, María Ángeles Puche Larrubia⁵, Miriam Ruiz-Ponce³, María del carmen Ábalos Aguilera³, Pedro Ortiz Buitrago³, Yasin Hanaee³, Carlos Perez-Sanchez⁶, Chary López-Pedrera³, Alejandro Escudero-Contreras⁷, Eduardo Collantes Estévez⁸ and Nuria Barbarroja⁹, ¹Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ⁶IMIBIC, Córdoba, Spain, ⁷Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, ⁸Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ⁹University of Cordoba, Córdoba, Spain
Background/Purpose: Chronic inflammation is closely associated with an increased risk of cardiovascular diseases (CVD) through the activation of the immune system and the release of…
Abstract Number: 2234 • ACR Convergence 2023
Disagreement Between Patient and Physician Global Assessment over Time in Psoriatic Arthritis: Insight into Treatment Priorities
Proton Rahman¹, Laura Coates², Peter Nash³, Atul Deodhar⁴, Francois Nantel⁵, Emmanouil Rampakakis⁶, Louis Bessette⁷, A. Marilise Marrache⁸, Frederic Lavie⁹, May Shawi¹⁰ and William R Tillett¹¹, ¹Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ²University of Oxford, Oxford, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁵Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁶McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁷Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁸Janssen Inc., Rheumatology and Biologics, Dollard-des-Ormeaux, QC, Canada, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰Immunology, Janssen Research & Development, LLC, Titusville, NJ, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: The PsA core domain set developed by the Outcome Measures in Rheumatology working group includes musculoskeletal disease, fatigue, physical function, and structural damage, of…
Abstract Number: 2220 • ACR Convergence 2023
Factors Associated with Achieving Remission in Patients with Early Peripheral Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
Murat Torgutalp¹, Xu Peng¹, Fabian Proft², Valeria Rios Rodriguez¹, Judith Rademacher¹, Mikhail Protopopov¹, Hildrun Haibel¹, Martin Rudwaleit³, Joachim Sieper¹ and Denis Poddubnyy⁴, ¹Charité Universitatsmedizine - Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Depending on leading manifestation, Spondyloarthritis (SpA) is classified as axial (axSpA) or peripheral SpA (pSpA). Achieving of remission/inactive disease is key goal in treatment…
Abstract Number: 2236 • ACR Convergence 2023
Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
Jeffrey R Curtis¹, Atul Deodhar², Enrique Soriano³, Emmanouil Rampakakis⁴, May Shawi⁵, Natalie shiff⁶, Marcie Strauss⁷, Chenglong Han⁸, William R Tillett⁹ and Dafna Gladman¹⁰, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷MEDASOURCE, Medical Group, Indianapolis, IN, ⁸Immunology, Janssen Global Services, LLC, Malvern, PA, ⁹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Guselkumab (GUS) has demonstrated robust efficacy across key PsA domains at Week (W) 24, with effects sustained or further enhanced through 2 years. Timing…
Abstract Number: 2229 • ACR Convergence 2023
Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
Laura Coates¹, Iain McInnes², Sibel Aydin³, Mitsumasa Kishimoto⁴, Philip J. Mease⁵, May Shawi⁶, Miriam Zimmermann⁷, Emmanouil Rampakakis⁸, Frederic Lavie⁹ and Dennis McGonagle¹⁰, ¹University of Oxford, Oxford, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, ⁴Kyorin University School of Medicine, Yokohoma, Japan, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁶Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁷Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁸McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients with mono/oligoarticular psoriatic arthritis (PsA), swelling or tenderness of specific joints can be associated with poorer patient-reported outcomes (PROs) and physician global…
Abstract Number: 2208 • ACR Convergence 2023
Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States
William Odell¹, Swetha Ann Alexander², Nicolas Page³, Narinder Maheshwari⁴ and Abhijeet Danve⁵, ¹Yale University, Wethersfield, CT, ²University of Utah Health, Salt Lake City, UT, ³Yale University, New Haven, CT, ⁴UCONN Health, Farmington, CT, ⁵Yale University School of Medicine, Glastonbury, CT
Background/Purpose: Average diagnostic delay for axial spondyloarthritis (axSpA) is 7 to 10 years. Lack of timely referral of inflammatory back pain (IBP) patients by non-rheumatology…
Abstract Number: 2145 • ACR Convergence 2023
Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study
Alicia Garcia Dorta¹, Andrea Hernández Martín², Cristina Rodríguez Regalado³, Sonia Isis Peña Montelongo⁴, Cristina Martínez González⁵, Elena Naveda-González², Enrique González-Dávila⁶, Jose Federico Diaz-Gonzalez⁷ and maría Vanesa Hernández Hernández⁵, ¹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Rheumatology Unit, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³Rheumatology Unit, Hospital Universitario Ntra Sra de la Candelaria, Santa Cruz de Tenerife, Spain, ⁴Rheumatology Unit, Hospital Virgen de la Peña, Fuerteventura, Spain, ⁵Rheumatology Unit, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ⁶Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ⁷Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: Based mainly on results from a randomized clinical trial (RCT) in rheumatoid arthritis (RA) patients (ORAL Surveillance), major regulatory agencies have concluded that JAK…
Abstract Number: 2001 • ACR Convergence 2023
Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis
Guy Katz¹, Aubree McMahon¹, Grace McMahon¹, Isha Jha¹, Marcy Bolster², Ana Fernandes¹, Zachary Wallace³, Cory Perugino¹, John Stone⁴ and Yasmin Hernandez-Barco¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Concord, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Metabolic bone disease (MBD), including osteopenia and osteoporosis, is common in patients with inflammatory disorders, due to disease factors and glucocorticoid (GC) use, and…
Abstract Number: 1785 • ACR Convergence 2023
Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis
Prakashini MV¹, Soumendu Mahapatra², Krushna Chandra Murmu², Rasmita Mishra², Prasanta Padhan¹, Punit Prasad², Ramnath Misra³ and Sakir Ahmed⁴, ¹Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India, ²Institute of Life Sciences, Bhubaneswar, India, ³Kalinga Institute of Medical Sciences, KIIT University, Lucknow, India, ⁴Kalinga Institute of Medical Sciences, Bhubaneswar, India
Background/Purpose: Reactive arthritis (ReA) is the unique infection-triggered spondyloarthritis (SpA). Undifferentiated peripheral SpA (UpSpA) is similar but without previous infection, or psoriasis or inflammatory bowel…
Abstract Number: 1797 • ACR Convergence 2023
Factors Associated with Distress Related to Perceived Dignity in Patients with Rheumatic Diseases
Virginia Pascual Ramos¹, Guillermo Guaracha Basañez², Irazú Contreras Yañez², Maximiliano Cuevas Montoya², Mario García Alanís², Oscar Rodríguez Mayoral³ and Harvey Max Chochinov⁴, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Servicio de Cuidados Paliativos, Instituto Nacional de Cancerología, Cuidad de Mexico, Mexico, ⁴Department of Psychiatry, University of Manitoba, Cancer Care Manitoba, Manitoba, MB, Canada
Background/Purpose: From the Human rights approach, dignity is accepted as a universal need, required for the well-being of every individual. It is an irrevocable feature…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].